Emergent BioSolutions Raises Full-Year Revenue Guidance

Emergent Biosolutions ( (EBS) ) has shared an announcement.

On October 29, 2025, Emergent BioSolutions reported its financial results for the third quarter of 2025, with total revenues of $231.1 million, surpassing its guidance by $21 million. Despite a decrease in revenues compared to the previous year, the company experienced strong growth in its naloxone franchise, driven by NARCAN® Nasal Spray, and secured multiple contract modifications for its medical countermeasures products. The company raised its full-year revenue and profitability guidance, reflecting confidence in its product demand and strategic positioning in the market.

The most recent analyst rating on (EBS) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.

Spark’s Take on EBS Stock

According to Spark, TipRanks’ AI Analyst, EBS is a Outperform.

Emergent Biosolutions’ overall stock score is driven by strong earnings call results and attractive valuation, indicating potential for growth. The company’s improved profitability and cash flow metrics are positive, though high leverage and declining revenue are concerns. Technical indicators support a bullish outlook, reinforcing the stock’s potential.

To see Spark’s full report on EBS stock, click here.

More about Emergent Biosolutions

Emergent BioSolutions Inc. operates in the biopharmaceutical industry, focusing on medical countermeasures against biological threats. Its primary products include NARCAN® Nasal Spray for opioid overdose, anthrax vaccines, and smallpox vaccines, with a significant market focus on international government contracts for medical countermeasures.

Average Trading Volume: 1,089,131

Technical Sentiment Signal: Buy

Current Market Cap: $505.2M

For detailed information about EBS stock, go to TipRanks’ Stock Analysis page.